<DOC>
	<DOCNO>NCT01860937</DOCNO>
	<brief_summary>The purpose study test safety give patient special cell make blood call `` Modified T-cells '' . The goal find safe dose modify T-cells patient whose leukemia return bone marrow .</brief_summary>
	<brief_title>T-Lymphocytes Genetically Targeted B-Cell Specific Antigen CD19 Pediatric Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>This phase I multicenter clinical trial pediatric young adult patient relapsed/refractory CD19+ B-ALL . The T cell dos originally propose study base dos administer safely prior T cell adoptive therapy trial , dose modify base toxicity observe adult patient morphologic evidence relapse B-ALL treat MSKCC IRB 09-114 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Inclusion Criteria Collection Arm protocol : Age &lt; 26 year , whose disease meet one follow 3 criterion : VHR* Patients 1st subsequent marrow relapse ( isolated combine ) , time relapse , retrieval therapy , achievement CR . Refractory disease *Definitions VHR BALL include follow : NCI HRALL age ≥ 13 year diagnosis CNS3 leukemia diagnosis Day 29/End Induction BM MRD &gt; 0.01 % Induction failure ( M3 BM Day 29/End Induction ) Hypodiploidy ( n &lt; 44 chromosome and/or DNA index &lt; 0.81 ) ( 9 ; 22 ) ALL ( Philadelphia Chromosome/Ph+ ALL ) ( 17 ; 19 ) ALL PhLike ALL MLL gene rearrangement IKZF1 deletion Intrachromosomal amplification chromosome 21 ( iAMP21 ) Please note patient meet criterion collection/storage PBMCs need reconsented prior infusion genetically modify Tcells . Inclusion Criteria Treatment Arm protocol : Patients must history relapsed/refractory CD19+ BALL involve marrow eligible infusion modify T cell . Please note ≥5 % blast morphology , FISH/cytogenetics , molecular translocation and/or flow cytometry constitute bone marrow relapse protocol . Patients must also fulfill one follow criterion eligible infusion modify T cell : Second great ( ≥2 ) relapse Early first marrow relapse ( 1st CR &lt; 18 month ) Intermediate/Late first marrow relapse ( 1st CR &gt; 18 month ) poor initial response ( ≥5 % blast morphology and/or flow cytometry ) follow reinduction chemotherapy Refractory Disease Ineligible HSCT determine treat physician consultation BMT service Patient would benefit additional chemotherapy determine treat physician KPS Lansky score ≥ 60 Pulmonary function ( measure prior condition chemotherapy ) : &gt; 90 % oxygen saturation room air pulse oximetry . Renal Function ( measure prior condition chemotherapy ) : Serum creatinine ≤2.0mg/dL patient 18 year ≤2.5 x institutional ULN age Hepatic Function ( measure prior condition chemotherapy ) : AST ≤ 5 x institutional ULN . Elevation secondary leukemic involvement exclusion criterion . Leukemic involvement determine presence progressive relapse define escalate bone marrow peripheral blood leukemia blast within previous month absence initiation know hepatotoxic medication ( e.g . azoles ) . Total bilirubin ≤ 2.5 x institutional ULN Exclusion Criteria Collection T cells/PBMCs : Karnofsky/Lansky performance status &lt; 60 . Patients concurrent active malignancy define malignancy require therapy expectant observation Patients active HIV , hepatitis B hepatitis C infection . Females pregnant Exclusion Criteria Treatment : Karnofsky/Lansky performance status &lt; 60 . Patients concurrent active malignancy define malignancy require therapy expectant observation Patients exclude isolated extramedullary relapse ALL Females pregnant . Patients active ( grade 24 ) acute graft versus host disease ( GVHD ) , chronic GVHD overt autoimmune disease ( e.g . hemolytic anemia ) follow alloHSCT require glucocorticosteroid treatment ( &gt; 0.5 mg/kg/day prednisone equivalent ) treatment . Active central nervous system ( CNS ) leukemia , define unequivocal morphologic evidence lymphoblast cerebrospinal fluid ( CSF ) within 7 day treatment symptomatic CNS leukemia ( i.e . cranial nerve palsy significant neurologic dysfunction ) within 28 day treatment . Prophylactic intrathecal medication reason exclusion . If LP traumatic ( contain RBCs ) repeat Steinherz/Bleyer ratio use determine unequivocal evidence CSF leukemia discretion treat physician . Uncontrolled , symptomatic , intercurrent illness include limited infection , psychiatric illness , social situation would limit compliance study requirement opinion treat investigator would pose unacceptable risk subject . Prior neurologic toxicity previous immunotherapy Preceding and/or ongoing organ dysfunction comorbidity include limited uncontrolled infection would impair patient 's ability endure know side effect cytokine release syndrome neurologic toxicity Recent prior therapy : Systemic chemotherapy le 2 week prior infusion apheresis ( 6 week clofarabine nitrosoureas apheresis ) radiation therapy less equal 3 week prior apheresis . Exceptions : oThere time restriction regard prior intrathecal chemotherapy provide complete recovery acute toxic effect . oSubjects receive hydroxyurea oral maintenance chemotherapy may enrol provided increase dose least 2 week prior start apheresis treatment . oSubjects receive steroid therapy physiologic replacement dos allow provided increase dose least 2 week prior start apheresis treatment . oSubjects must recover acute side effect prior therapy , eligibility criterion meet . Cytopenias deem diseaserelated therapyrelated exempt exclusion . •Rapidly progressive disease estimation treat physician would compromise ability complete study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>T cell Immunotherapy</keyword>
	<keyword>CD19 Targeted Therapy</keyword>
	<keyword>Chimeric Antigen Receptor ( CAR ) Modified T cell</keyword>
	<keyword>Conditioning Chemotherapy</keyword>
	<keyword>13-052</keyword>
</DOC>